Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET

Imaging of prostate cancer presents many challenges to the imaging community. There has been much progress in this space in large part due to MRI and PET radiopharmaceuticals. Though MRI has been focused on the evaluation of local disease and PET on the detection of metastatic disease, these two areas do converge and will be complementary especially with the growth of new PET/MRI technologies. In this review article, we review novel MRI, MRI/US, and PET radiopharmaceuticals which will offer insight into the future direction of imaging in prostate cancer.

[1]  P. Choyke,et al.  Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease , 2014 .

[2]  J. Votaw,et al.  A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  S. Ramin,et al.  Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literature , 2013, BJU international.

[4]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[5]  R. Lenkinski,et al.  Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 tesla endorectal, in vivo T2‐weighted MR imagery , 2012, Journal of magnetic resonance imaging : JMRI.

[6]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[7]  T. Shiga,et al.  Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  I. Jambor,et al.  In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.

[9]  P. P. Iu,et al.  ESUR prostate MR guidelines. , 2013, European radiology.

[10]  J. Humm,et al.  Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET , 2010, Journal of Nuclear Medicine.

[11]  J. Nelson,et al.  Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model , 2003, The Prostate.

[12]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[13]  H. Jadvar.  Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.

[14]  M. Morris,et al.  Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer* , 2008, Journal of Nuclear Medicine.

[15]  A. Kibel,et al.  11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction , 2013, The Journal of Nuclear Medicine.

[16]  L. Bu,et al.  A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[17]  H. Jadvar.  Molecular imaging of prostate cancer: PET radiotracers. , 2012, AJR. American journal of roentgenology.

[18]  W. Lowrance,et al.  Castration-resistant prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[19]  G. Slegers,et al.  Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? , 2001, Nuclear medicine communications.

[20]  Andrew B Rosenkrantz,et al.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. , 2014, The Journal of urology.

[21]  H. Shinmoto,et al.  Diffusion kurtosis imaging study of prostate cancer: Preliminary findings , 2014, Journal of magnetic resonance imaging : JMRI.

[22]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  C. Dence,et al.  Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  E. Crawford,et al.  The Accuracy of Prostate Cancer Localization Diagnosed on Transrectal Ultrasound-Guided Biopsy Compared to 3-Dimensional Transperineal Approach , 2013, Advances in urology.

[25]  A. Fenster,et al.  Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. , 2015, AJR. American journal of roentgenology.

[26]  Steve Y. Cho,et al.  New Agents and Techniques for Imaging Prostate Cancer , 2009, Journal of Nuclear Medicine.

[27]  Bachir Taouli,et al.  Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice , 2015, Journal of magnetic resonance imaging : JMRI.

[28]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[29]  Hossein Jadvar,et al.  Molecular Imaging of Prostate Cancer with PET , 2013, The Journal of Nuclear Medicine.

[30]  C W Piccoli,et al.  Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. , 1994, Radiology.

[31]  I. Burger,et al.  Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[32]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[33]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[34]  Ji-gang Yang,et al.  The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis , 2016, Acta radiologica.

[35]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[36]  F. Bladou,et al.  Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest , 2015, World Journal of Urology.

[37]  S. Kridel,et al.  1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer , 2008, Journal of Nuclear Medicine.

[38]  J. Nesland,et al.  Transperineal prostate biopsy detects significant cancer in patients with elevated prostate‐specific antigen (PSA) levels and previous negative transrectal biopsies , 2012, BJU international.

[39]  F. Bowman,et al.  Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. , 2014, The Journal of urology.

[40]  Marc Lemort,et al.  MRI-Targeted Biopsies versus Systematic Transrectal Ultrasound Guided Biopsies for the Diagnosis of Localized Prostate Cancer in Biopsy Naïve Men , 2015, BioMed research international.

[41]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[42]  Kemal Tuncali,et al.  Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. , 2015, Radiology.

[43]  Magnus Dahlbom,et al.  Radiation dose estimates in humans for (11)C-acetate whole-body PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  G Nilsson,et al.  Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. , 1979, Biochemical and biophysical research communications.

[45]  V. Erspamer,et al.  Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the european amphibiansBombina andAlytes , 1971, Experientia.

[46]  D. Nieboer,et al.  Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. , 2015, European urology.

[47]  S. Mather,et al.  Targeting prostate cancer with radiolabelled bombesins , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[48]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[49]  E J Halpern,et al.  Using gray-scale and color and power Doppler sonography to detect prostatic cancer. , 2000, AJR. American journal of roentgenology.

[50]  S. Balk,et al.  Mechanisms mediating androgen receptor reactivation after castration. , 2009, Urologic oncology.

[51]  Toby C. Cornish,et al.  18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[52]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[53]  G. Baldwin,et al.  Expression and function of gastrin‐releasing peptide (GRP) in normal and cancerous urological tissues , 2014, BJU international.

[54]  F DuBois Bowman,et al.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[56]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Jurgen J Fütterer,et al.  Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.

[58]  Martin G Pomper,et al.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen. , 2013, Current topics in medicinal chemistry.

[59]  Y. Yamashita,et al.  Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation , 2010, European Radiology.

[60]  J. Habener,et al.  Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Katarzyna J Macura,et al.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. , 2009, Radiology.

[62]  E. Crawford,et al.  Challenges and recommendations for early identification of metastatic disease in prostate cancer. , 2014, Urology.

[63]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[64]  Pierre Mozer,et al.  First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancer , 2015, BJU international.

[65]  M J Bronskill,et al.  Magnetic resonance imaging of the prostate. , 1985, Radiology.

[66]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[67]  Heinz-Peter Schlemmer,et al.  Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. , 2015, The Journal of urology.

[68]  Mohammad H. Mahoor,et al.  Diagnosis of prostatic Carcinoma on multiparametric magnetic resonance imaging using shearlet transform , 2014, 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[69]  N. Shikano,et al.  Putative Transport Mechanism and Intracellular Fate of Trans-1-Amino-3-18F-Fluorocyclobutanecarboxylic Acid in Human Prostate Cancer , 2011, Journal of Nuclear Medicine.

[70]  G. Koning,et al.  A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[71]  Baris Turkbey,et al.  Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer , 2015, Abdominal Imaging.

[72]  P. Choyke,et al.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. , 2014, Radiology.

[73]  W. Oyen,et al.  Molecular Imaging of Prostate Cancer: Tapping into the Opportunities , 2015, The Journal of Nuclear Medicine.

[74]  H. Kung,et al.  Oncogenic activation of androgen receptor. , 2009, Urologic oncology.

[75]  John Kurhanewicz,et al.  Hyperpolarized 13C MR for Molecular Imaging of Prostate Cancer , 2014, The Journal of Nuclear Medicine.

[76]  Serge K. Lyashchenko,et al.  A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. , 2014, The Journal of urology.

[77]  Jin Tae Kwak,et al.  Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. , 2015, Medical physics.

[78]  Jens Sörensen,et al.  [18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology , 2009, European Journal of Nuclear Medicine and Molecular Imaging.